{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:48:20Z","timestamp":1784569700180,"version":"3.55.0"},"reference-count":71,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hungarian Government","award":["GINOP-2.3.3-15-2016-00031"],"award-info":[{"award-number":["GINOP-2.3.3-15-2016-00031"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Stroke embodies one of the leading causes of death and disability worldwide. We aimed to provide a comprehensive insight into the effectiveness and safety of antiplatelet agents and anticoagulants in the secondary prevention of ischemic stroke or transient ischemic attack. A systematic search for randomized controlled trials, comparing antiplatelet or anticoagulant therapy versus aspirin or placebo among patients with ischemic stroke or transient ischemic attack, was performed in order to summarize data regarding the different regimens. Keyword-based searches in the MEDLINE, EMBASE, and Cochrane Library databases were conducted until the 1st of January 2021. Our search explored 46 randomized controlled trials involving ten antiplatelet agents, six combinations with aspirin, and four anticoagulant therapies. The review of the literature reflects that antiplatelet therapy improves outcome in patients with ischemic stroke or transient ischemic attack. Monotherapy proved to be an effective and safe choice, especially in patients with a high risk of bleeding. Intensified antiplatelet regimens further improve stroke recurrence; however, bleeding rate increases while mortality remains unaffected. Supplementing the clinical judgment of stroke treatment, assessment of bleeding risk is warranted to identify patients with the highest benefit of treatment intensification.<\/jats:p>","DOI":"10.3390\/life11050447","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T23:17:16Z","timestamp":1621207036000},"page":"447","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antithrombotic Therapy for Secondary Prevention in Patients with Non-Cardioembolic Stroke or Transient Ischemic Attack: A Systematic Review"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1406-4016","authenticated-orcid":false,"given":"D\u00e1niel","family":"Tornyos","sequence":"first","affiliation":[{"name":"Department of Interventional Cardiology, Heart Institute, Medical School, University of P\u00e9cs, Ifj\u00fas\u00e1g \u00fatja 13, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-8633","authenticated-orcid":false,"given":"Alexandra","family":"B\u00e1lint","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Heart Institute, Medical School, University of P\u00e9cs, Ifj\u00fas\u00e1g \u00fatja 13, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Kup\u00f3","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Heart Institute, Medical School, University of P\u00e9cs, Ifj\u00fas\u00e1g \u00fatja 13, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumaima El Alaoui","family":"El Abdallaoui","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Heart Institute, Medical School, University of P\u00e9cs, Ifj\u00fas\u00e1g \u00fatja 13, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Kom\u00f3csi","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Heart Institute, Medical School, University of P\u00e9cs, Ifj\u00fas\u00e1g \u00fatja 13, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association\/American Stroke A","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"E139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics\u20142020 update: A report from the American heart association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(03)00266-7","article-title":"Stroke epidemiology: A review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century","volume":"2","author":"Feigin","year":"2003","journal-title":"Lancet Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/CIRCRESAHA.116.308413","article-title":"Global burden of stroke","volume":"120","author":"Feigin","year":"2017","journal-title":"Circ. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJMcp072057","article-title":"Clinical practice. Acute ischemic stroke","volume":"357","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_8","unstructured":"Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Blomstr\u00f6m-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., and Dilaveris, P.E. (2020). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"The Canadian Cooperative Study Group (1978). A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N. Engl. J. Med., 299, 53\u201359.","DOI":"10.1056\/NEJM197807132990201"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"(1991). The Salt Collaborative Group Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet, 338, 1345\u20131349.","DOI":"10.1016\/0140-6736(91)92233-R"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"Gent","year":"1996","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1124\/jpet.104.079780","article-title":"Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-\u03b1 formation in low-density lipoprotein receptor-null mice fed high cholesterol","volume":"313","author":"Lee","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/1747493018786616","article-title":"Canadian stroke best practice recommendations for acute stroke management: Prehospital, emergency department, and acute inpatient stroke care, 6th edition, update 2018","volume":"13","author":"Boulanger","year":"2018","journal-title":"Int. J. Stroke"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wang, Y., Chen, W., Lin, Y., Meng, X., Chen, G., Wang, Z., Wu, J., Wang, D., Li, J., and Cao, Y. (2019). Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: Open label, blinded endpoint, randomised controlled phase II trial. BMJ, 365.","DOI":"10.1136\/bmj.l2211"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.114.014791","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial one-year outcomes","volume":"132","author":"Wang","year":"2015","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1474-4422(09)70361-8","article-title":"Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): A randomised, open-label, blinded-endpoint trial","volume":"9","author":"Dengler","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2011.09.038","article-title":"Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: A pilot study","volume":"313","author":"Nakamura","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Farrant","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/01.STR.8.3.301","article-title":"Controlled trial of aspirin in cerebral ischemia","volume":"8","author":"Fields","year":"1977","journal-title":"Stroke"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/01.STR.14.1.15","article-title":"Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study","volume":"14","author":"Sorensen","year":"1983","journal-title":"Stroke"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1161\/01.STR.18.2.325","article-title":"Original contributions high-dose acetylsalicylic acid after cerebral infarction","volume":"18","author":"Britton","year":"1987","journal-title":"Stroke"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","article-title":"The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results","volume":"54","author":"Farrell","year":"1951","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke","volume":"349","author":"Sandercock","year":"1997","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","article-title":"CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke","volume":"349","author":"Chen","year":"1997","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.289.22.2947","article-title":"Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial","volume":"289","author":"Gorelick","year":"2003","journal-title":"J. Am. Med. Assoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2169\/internalmedicine.42.793","article-title":"Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke","volume":"42","author":"Ito","year":"2003","journal-title":"Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The canadian american ticlopidine study (Cats) in thromboembolic stroke","volume":"333","author":"Gent","year":"1989","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","article-title":"A Randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients","volume":"321","author":"Hass","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000111498","article-title":"A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in japanese patients with noncardioembolic cerebral infarction","volume":"25","author":"Fukuuchi","year":"2008","journal-title":"Cerebrovasc. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s00415-009-5035-4","article-title":"The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: Combined results of two Phase III, multicenter, randomized clinical trials","volume":"256","author":"Uchiyama","year":"2009","journal-title":"J. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1016\/0006-2952(84)90103-5","article-title":"Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography","volume":"33","author":"Hayato","year":"1984","journal-title":"Biochem. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"56B","DOI":"10.1016\/S0828-282X(06)70987-4","article-title":"The vascular effects of cilostazol","volume":"22","author":"Weintraub","year":"2006","journal-title":"Can. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/01.CIR.0000117403.64398.53","article-title":"Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: Prevention by cilostazol","volume":"109","author":"Shin","year":"2004","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1124\/jpet.300.3.787","article-title":"Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats","volume":"300","author":"Choi","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0021-9150(01)00431-2","article-title":"Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-\u03baB binding to its recognition sequence","volume":"158","author":"Otsuki","year":"2001","journal-title":"Atherosclerosis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/hh0202.104108","article-title":"Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation","volume":"90","author":"Rybalkin","year":"2002","journal-title":"Circ. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosissup.2005.09.002","article-title":"Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding","volume":"6","author":"Goto","year":"2005","journal-title":"Atheroscler. Suppl."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/jscd.2000.7216","article-title":"Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction","volume":"9","author":"Gotoh","year":"2000","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(08)70094-2","article-title":"Cilostazol as an alternative to aspirin after ischaemic stroke: A randomised, double-blind, pilot study","volume":"7","author":"Huang","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1474-4422(18)30128-5","article-title":"Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): A multicentre, randomised controlled trial","volume":"17","author":"Kim","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/bmj.1.5644.614","article-title":"Controlled trial of dipyridamole in cerebral vascular disease","volume":"1","author":"Acheson","year":"1969","journal-title":"Br. Med. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/01.STR.21.8.1122","article-title":"European stroke prevention study. ESPS group","volume":"21","author":"Jan","year":"1990","journal-title":"Stroke"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"J. Neurol. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.STR.14.1.5","article-title":"\u201cAICLA\u201d controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia","volume":"14","author":"Bousser","year":"1983","journal-title":"Stroke"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/01.STR.16.3.406","article-title":"Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-canadian co-operative study group","volume":"16","author":"Fields","year":"1985","journal-title":"Stroke"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial","volume":"367","author":"Halkes","year":"2006","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1159\/000327035","article-title":"The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: A randomized, Double-blind, controlled trial","volume":"31","author":"Uchiyama","year":"2011","journal-title":"Cerebrovasc. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1747-4949.2010.00535.x","article-title":"Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: A substudy of the CHARISMA trial","volume":"6","author":"Hankey","year":"2011","journal-title":"Int. J. Stroke"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMoa1204133","article-title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke","volume":"367","author":"Benavente","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1474-4422(07)70250-8","article-title":"Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): A randomised controlled pilot trial","volume":"6","author":"Kennedy","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jocn.2014.05.038","article-title":"Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke","volume":"22","author":"He","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.01.022","article-title":"A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke","volume":"23","author":"Yi","year":"2014","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.STR.13.2.175","article-title":"A randomized trial of aspirin and sulfinpyrazone in patients with TIA","volume":"13","author":"Candelise","year":"1982","journal-title":"Stroke"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(81)91732-3","article-title":"Randomised trial of pentoxifylline versus acetylsalicylic acid plus dipyridamole in preventing transient ischaemic attacks","volume":"317","author":"Herskovits","year":"1981","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1212\/01.WNL.0000113757.34662.AA","article-title":"Triflusal vs aspirin for prevention of cerebral infarction: A randomized stroke study","volume":"62","author":"Culebras","year":"2004","journal-title":"Neurology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1161\/STROKEAHA.107.505131","article-title":"Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial","volume":"39","author":"Shinohara","year":"2008","journal-title":"Stroke"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","article-title":"A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke","volume":"345","author":"Mohr","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa043033","article-title":"Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis","volume":"352","author":"Chimowitz","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"Hart","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source","volume":"380","author":"Diener","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jns.2019.02.037","article-title":"Comparative efficacy and safety of multiple antiplatelet therapies for secondary prevention of ischemic stroke or transient ischemic attack: A network meta-analysis","volume":"399","author":"Xiang","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ahj.2006.04.012","article-title":"Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: Design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)","volume":"152","author":"Wiviott","year":"2006","journal-title":"Am. Heart J."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Elhorany, M., Lenck, S., Degos, V., Sourour, N.A., Frasca Polara, G., Shotar, E., Godier, A., Drir, M., Mahtout, J., and Premat, K. (2020). Cangrelor and stenting in acute ischemic stroke: Monocentric case series. Clin. Neuroradiol., 1\u201310.","DOI":"10.26226\/morressier.5e8335ba7cb08a046ef7c7a3"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1517\/14656566.2012.699522","article-title":"Cost-effectiveness of stroke treatments and secondary preventions","volume":"13","author":"Pan","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Pan, Y., Wang, A., Liu, G., Zhao, X., Meng, X., Zhao, K., Liu, L., Wang, C., Claiborne Johnston, S., and Wang, Y. (2014). Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. J. Am. Heart Assoc., 3.","DOI":"10.1161\/JAHA.114.000912"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1161\/STROKEAHA.118.023978","article-title":"Optimal duration of aspirin plus clopidogrel after ischemic stroke or transient ischemic attack: A systematic review and meta-analysis","volume":"50","author":"Rahman","year":"2019","journal-title":"Stroke"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/5\/447\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:02:07Z","timestamp":1760162527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/5\/447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,15]]},"references-count":71,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["life11050447"],"URL":"https:\/\/doi.org\/10.3390\/life11050447","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,15]]}}}